GLP-1 Receptor Agonists, Explained

GLP-1 receptor agonists are a class of medication that has drawn a great deal of attention in recent years — both for managing blood glucose in type 2 diabetes and for their effect on weight. This is a plain-language explainer of how the class works and what to understand about it in general terms. It is educational, not medical advice: whether one of these medicines is appropriate for any individual is a decision made with a qualified clinician.

This article is part of our type 2 diabetes guide and expands on one class from our medications overview.

Mimicking a natural gut hormone

The name is a clue to how these medicines work. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating; it is one of the body's incretin hormones. A "receptor agonist" is a medicine that activates the same receptors that the natural hormone would. In other words, GLP-1 receptor agonists imitate a signal the body already uses to help manage glucose after meals.

What the class does

By activating GLP-1 receptors, these medications produce several effects at once:

• Enhance glucose-dependent insulin release. They prompt the pancreas to release more insulin when blood glucose is high — the "glucose-dependent" part means this effect eases as glucose falls, which helps limit the risk of low blood sugar.
• Lower glucagon. They reduce glucagon, a hormone that raises blood glucose, further helping to keep levels in check.
• Slow gastric emptying. By slowing how quickly the stomach empties, they blunt post-meal glucose spikes and increase the feeling of fullness.
• Reduce appetite. Acting on appetite signals, they often help people eat less, which is why the class frequently supports weight loss alongside better glucose control.

Common examples and how they're taken

Medicines in this class include semaglutide, liraglutide, and dulaglutide, among others. Most are given by injection — some daily, some once weekly — and an oral (tablet) form also exists. The specific medicine, how often it is taken, and whether it is injectable or oral are all matters a clinician decides with the individual, factoring in the whole clinical picture.

Benefits beyond glucose, and common side effects

Part of the interest in this class comes from evidence that some GLP-1 receptor agonists offer benefits beyond glucose: several have shown cardiovascular benefit in studies for certain groups of people, and the weight effect can be meaningful for many. This is one reason the American Diabetes Association's Standards of Care describe treatment as tailored to the whole person, not glucose alone.

The most common side effects are gastrointestinal — nausea is the frequent one — and these often lessen as the body adjusts. As with any class, there are considerations that a clinician weighs individually, which is why suitability, choice, and monitoring are clinician-led. For people focused on the bigger picture, our guide on type 2 diabetes remission discusses how glucose, weight, and lifestyle interact over the longer term.

How it fits into care

GLP-1 receptor agonists are one option among several, and are often discussed alongside or after metformin depending on a person's needs and other conditions. Any decision to start, change, or stop a medication belongs with a qualified clinician. Endobits is clinical decision-support software used under clinician oversight — it helps organise and interpret glucose data to support those conversations, and it is not a prescriber.

Sources

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — Insulin, Medicines, & Other Diabetes Treatments. American Diabetes Association — Standards of Care in Diabetes (Pharmacologic Approaches to Glycemic Treatment). U.S. Food and Drug Administration — Drugs (prescribing information and safety).

Related: The type 2 diabetes guide · Medications overview · Metformin, explained · Type 2 diabetes remission · Glossary